Astrana Health Inc. filings document the regulatory record for a physician-centric, technology-enabled healthcare management company. Current reports on Form 8-K furnish operating results, earnings presentations, Regulation FD materials, and investor-presentation exhibits tied to the company's care model, provider networks, technology platform, and financial performance.
Proxy filings cover annual-meeting governance matters, including director elections, auditor ratification, executive compensation votes, and equity incentive plan approvals. Other filings address reporting status through Form 12b-25 notices and material-event disclosures related to completed acquisitions, including acquired-business financial statements and pro forma operating information.
Astrana Health, Inc. CEO and President Brandon Sim reported surrendering 9,889 common shares at $37.00 per share on October 6, 2026, to offset tax withholding on restricted stock units that vested that day. His reported direct holdings afterward were 1,228,972 shares. The Sim Family Irrevocable Trust 2021 held 258,824 shares, and the Brandon Sim 2020 Irrevocable Trust held 392,816 shares; Sim disclaims beneficial ownership of those trust shares except to the extent of his pecuniary interest.
Astrana Health, Inc. director Thomas S. Lam reported surrendering 2,624 directly held shares on October 6, 2026, at $37.00 per share, to offset tax withholding on restricted stock units that vested that day. He held 463,033 shares directly afterward. Separate indirect holdings were 6,132,802 shares held by Allied Physicians of California, a Professional Medical Corporation, and 1,133,706 shares held by the Thomas and Jeanette Lam 2002 Family Trust; Lam disclaimed beneficial ownership of Allied Physicians’ shares except to the extent of his pecuniary interest.
Astrana Health, Inc. COO and CFO Chandan Basho surrendered 2,092 common shares on October 2, 2026, to offset tax-withholding obligations associated with restricted stock units that vested that day. The reported price per share was $35.88. His resulting direct position was 155,728 shares, including unvested restricted stock and restricted stock units subject to continuous employment.
Astrana Health, Inc. updated its corporate presentation and reported second-quarter 2026 revenue of $972.5 million, up 48% from the prior-year quarter, and Adjusted EBITDA of $68.9 million, compared with $48.1 million. Free cash flow was $92.9 million for the six months ended June 30, 2026.
Management raised full-year 2026 Adjusted EBITDA guidance to $255 million–$280 million, citing first-half outperformance, and reaffirmed revenue guidance of $3.8 billion–$4.1 billion and free cash flow guidance of $105 million–$132.5 million. General and administrative expenses were 5.6% of revenue in Q2 2026, versus 7.7% in Q2 2025; management expects to exit 2026 at approximately 6%.
The presentation describes approximately 1.5 million members in value-based arrangements, more than 20,000 providers and operations in 18 markets. Care Enablement had $340 million of revenue for the twelve months ended June 30, 2026, with a 43% gross margin and a 21% operating margin.
Astrana Health, Inc. disclosed a cybersecurity incident that it determined was material as of September 22, 2026. Its subsidiary detected unusual activity involving social-engineering attempts to obtain access to company systems. The company says certain private or confidential information on its servers was accessed and/or acquired without authorization, and it is assessing whether patient, employee, provider, business, financial, or intellectual-property information was affected.
Astrana responded by resetting affected credentials, restricting remote access tools, restoring certain systems from clean backups, and enhancing monitoring. Its investigation is ongoing; it has notified law enforcement and is notifying regulators and payer partners. The company cannot yet estimate the incident’s full potential impact, but currently does not expect a material effect on its financial condition or results of operations. Its cybersecurity insurance may cover certain losses.
Astrana Health, Inc. executive John Vong, SVP – Accounting (PAO), reported a Form 4 showing a disposition of 96 shares of common stock on September 15, 2026, to pay tax withholding obligations tied to vesting restricted stock units. After this tax-withholding transaction, he directly holds 22,330 shares, including restricted stock, shares acquired under the Employee Stock Purchase Plan, and additional restricted stock units scheduled to vest over time. No Rule 10b5-1 trading plan is reported.
Astrana Health, Inc. (ASTH) furnished an updated investor presentation outlining its AI-enabled, value-based care model, recent performance, and 2026 outlook. The company reports operating at scale with about 1.5 million members in value-based arrangements and more than 20,000 providers caring for these members across 16 markets.
Revenue for 2025 was $3.18 billion with Adjusted EBITDA of $205.4 million, and the company reiterates a medium-term goal of 15–20% annual Adjusted EBITDA growth. For 2026, guidance calls for total revenue of $3.8–$4.1 billion, Adjusted EBITDA of $255–$280 million, and free cash flow of $105–$132.5 million. Q2 2026 revenue was $972.5 million with Adjusted EBITDA of $68.9 million and a 7.1% Adjusted EBITDA margin, supported by G&A improving 210 basis points year over year to 5.6% of revenue. Astrana highlights an AI-native operating platform that automates prior authorizations and claims adjudication, and emphasizes a continued shift toward full-risk contracts, which represented 81% of Q2 2026 capitation revenue, while noting a previously disclosed material weakness in internal control over financial reporting.
Astrana Health, Inc. (ASTH) reported that CEO and President Brandon Sim surrendered 7,163 shares of common stock on September 5, 2026 to pay tax withholding obligations associated with vested restricted stock units, at a reported price of $38.47 per share. This tax-withholding disposition did not involve an open-market sale and no Rule 10b5-1 trading plan is reported. Following the transaction, he holds 1,238,861 shares directly, including unvested restricted stock and restricted stock units scheduled to vest over multiple semi-annual installments, and also has indirect interests in shares held by two irrevocable trusts, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Astrana Health, Inc. (ASTH) reported that its COO and CFO, Basho Chandan, had 1,790 shares of common stock withheld on September 5, 2026 to pay tax liabilities associated with vested restricted stock units, at a value of $38.47 per share. After this tax-withholding disposition, he holds 157,820 shares directly, including 15,202 shares of unvested restricted stock and additional restricted stock units scheduled to vest over time, all subject to continuous employment with Astrana Health.
Astrana Health, Inc. (ASTH) reported that director Mitchell W. Kitayama disposed of shares of common stock in a transaction recorded as a disposition to the issuer. On 2026-08-31, 8,500 shares were repurchased by Astrana Health at $37.09 per share. Following this repurchase, Kitayama directly holds 24,337 shares, including 4,991 shares of restricted stock that will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders.